This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., March 14, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 25
th Annual ROTH Conference, which will be held at the Ritz Carlton, Laguna Nigel in Dana Point, California.
Jonae R. Barnes, Vice President of Investor Relations and Corporate Communications of Agenus, will present a corporate overview on Monday, March 18
th in Salon 5, Pink at 3:00 pm PT.
Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon
1 is being studied in clinical trials for 17 vaccine indications. They include:
Phase 3: GSK's RTS,S for malaria 2
Phase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with resected melanoma 2
Phase 3: GSK's MAGE-A3 cancer immunotherapy for selected patients with resected non-small cell lung cancer 2
Phase 3: GSK's HZ/su for shingles 2
Phase 2: Janssen's ACC-001 for Alzheimer's disease
Agenus pipeline programs include:
Phase 2: HerpV (contains QS-21 Stimulon) for genital herpes
Phase 2: Prophage Series G-100 for newly diagnosed glioma
Phase 2: Prophage Series G-200 for recurrent glioma
Saponin Platform: QS-21 Stimulon®Adjuvant
Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally entitled to receive milestone payments as QS-21 Stimulon-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
Heat Shock Protein Platform: Recombinant Series HerpV
HerpV is the most advanced HSV-2 therapeutic vaccine currently in clinical development for the treatment of genital herpes. A Phase 2 study measuring the effect of vaccination on viral shedding in individuals infected with HSV-2 is underway. Data results for this study are anticipated in Q4'13. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into the clinical benefit of a reduction in recurrent outbreaks.